Effects of Dihydromyricetin on Blood Lipid Metabolism and Antioxidation in Atherosclerosis Rats
10.3870/yydb.2015.06.002
- VernacularTitle:藤茶双氢杨梅素对动脉粥样硬化大鼠血脂代谢及抗氧化作用的影响
- Author:
Zhudi LIANG
;
Xianbiao ZENG
;
Guining WEI
;
Fei HE
;
Jihua LYU
;
Hua SU
;
Baowei WEI
- Publication Type:Journal Article
- Keywords:
Dihydromyricetin;
Atherosclerosis;
Blood lipid;
Antioxidation
- From:
Herald of Medicine
2015;(6):710-713
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effect of dihydromyricetin of ampelopsis grossedentata on lipid metabolism and antioxidation in atherosclerosis (AS) rats. Methods Sixty Wistar rats were randomly divided into five groups (n = 12 each):normal control group, model control group, positive control group, high dose dihydromyricetin group (40 mg·kg-1 ) and low dose dihydromyricetin group (10 mg·kg-1 ). Except normal control group, rats in the other groups were injected with a single dose of vitamin D3(600 000 U·kg-1 ) and loaded with high fat diet to establish AS model. Simvastatin (5 mg·kg-1 ) was intragastrically administered to positive control group. High and low dose dihydromyricetin groups received intragastric administration of 40 and 10 mg·kg-1 dihydromyricetin, respectively. Equal volume of purified water was given to normal and model group. After 24 weeks of administration, serum levels of lipids, activities of superoxide-dismutase (SOD) and malonicdialdehyde (MAD) were determined. Results As compared with model control group, triglycerides (TG) of high and low dose dihydromyricetin groups was decreased [(191. 65±101. 10) vs. (111. 10±29. 29) and (120. 55±38. 12) mg·L-1 , respectively], total cholesterol (TC) was decreased [(151. 64±33. 62) vs. (148. 49±30. 14) and (118. 90±27. 38) mg·L-1 ], and high density lipoprotein cholesterol (HDL-C) was increased [(1. 29±0. 68) vs. (2. 10±0. 70) and (1. 62±0. 61) mmol·L-1 ], low density lipoprotein cholesterol (LDL-C) was decreased [(5. 01±1. 33) vs. (3. 97±0. 78) and (4. 28±0. 79) mmol·L-1 ], activity of SOD was increased [(141. 03±42. 52) vs. (187. 97±42. 08) and (150. 99±46. 17) U·mL-1 ], and MDA was decreased [(20. 51±3. 81) vs. (17. 64±1. 54) and (18. 52± 3. 42) nmol·mL-1 ], with significant differences (P<0. 05, P<0. 01). Conclusion Dihydromyricetin can reduce the level of serum lipid, improve antioxidation activity, and has therapeutic effect for atherosclerosis.
